Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism
- Conditions
- Hypoparathyroidism
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Ascendis Pharma Bone Diseases A/S
- Registration Number
- NCT05654701
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism
Phase 3
Completed
- Conditions
- HypoparathyroidismEndocrine System DiseasesParathyroid Diseases
- Interventions
- Combination Product: PlaceboCombination Product: TransCon PTH
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Ascendis Pharma Bone Diseases A/S
- Target Recruit Count
- 84
- Registration Number
- NCT04701203
- Locations
- 🇳🇴
Ascendis Pharma Investigational Site, Oslo, Norway
© Copyright 2025. All Rights Reserved by MedPath